Experience with micronized progesterone used in combined hormone therapy in periand postmenopausal women
- 作者: Yarmolinskaya M.I.1,2
-
隶属关系:
- D.O. Ott Research Institute of Obstetrics and Gynecology, North-Western Branch, Russian Academy of Medical Sciences
- I.I. Mechnikov North-Western State Medical University
- 期: 编号 9 (2014)
- 页面: 108-113
- 栏目: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247313
- ID: 247313
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Objective. To evaluate the efficiency and safety of micronized progesterone as part of combined menopausal hormone therapy (MHT) in peri- and postmenopausal women. Subject and methods. Two groups of peri- and postmenopausal patients with climacteric syndrome receiving intermittent and continuous combined MHT regimens in accordance with the climacteric phase were examined. Results. The choice of a transdermal or intravaginal administration route for the hormonal components of MHT was substantiated in terms of a somatic disease in women and the efficiency and safety of these therapy regimens were evaluated. Conclusion. Prajisun used as part of different therapy regimens in women with varying degrees of climacteric syndrome shows good tolerability, effective endometrial control, and a low frequency of adverse reactions and it may be a drug of choice as a progestagenic component of combined MHT.
全文:
作者简介
Maria Yarmolinskaya
D.O. Ott Research Institute of Obstetrics and Gynecology, North-Western Branch, Russian Academy of Medical Sciences; I.I. Mechnikov North-Western State Medical University
Email: m.yarmolinskaya@gmail.com
MD, leading scientific researcher of the department of Gynecological Endocrinology, D.O. Ott Research Institute of Obstetrics and Gynecology, North-Western Branch, Russian Academy of Medical Sciences, professor of I.I. Mechnikov North-Western State Medical University.
参考
- Sturdee D.W., Pines A., Archer D.F., Baber R.J., Barlow D., Birkhauser M.H. et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2011; 14: 302-20.
- De Villiers T. J., Gass M.L.S, Haines C.J., Hall J.E., Lobo R.A., Pierro D.D., Rees M. Global consensus statement on menopausal hormone therapy. Climacteric. 2013; 16(2): 203-4.
- Тарасова М.А., Ярмолинская М.И. Принципы индивидуального выбора гормональной заместительной терапии в пери- и постменопаузе. Практическое пособие для врачей. 2-е изд. СПб.: Издательство Н-Л; 2011. 61 с. [Tarasova M.A., Yarmolinskaya M.I. Principles of individual choice of hormone replacement therapy in peri- and postmenopausal women. A practical guide for physicians. 2nd ed. St. Petersburg: Publisher H-L; 2011. 61 p.]
- Panay N., Hamoda H., Arya R., Savvas М. The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int. 2013; 19(2): 59-68.
- Ярмолинская М.И., Цыпурдеева А.А., Долинский А.К., Коган И.Ю., Баранов B.C., Кветной И.М. и др. Миома матки. Этиология, патогенез, принципы диагностики. Пособие для врачей. СПб.: Издательство Н-Л; 2013. 78 с. [Yarmolinskaya M.I., Tsypurdeeva A.A., Dolinsky A.K., Kogan I.Yu., Baranov V.S., Kvetnoy I.M. et al. Hysteromyoma. Etiology, pathogenesis, principles of diagnosis. Manual for physicians. St. Petersburg: Publisher H-L; 2013. 78 p.]
- Fournier A., Dossus L., Mesrine S., Vilier A., Boutron-Ruault M.C., Clavel-Chapelon F., Chabbert-Buffet N. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N Cohort, 1992-2008. Am. J. Epidemiol. 2014; Jul 9. pii: kwu146.
- Мусина Е.В. Механизмы влияния и эффективность препаратов прогестерона при фиброзно-кистозной болезни молочных желез в репродуктивном возрасте: Автореф. дис.. канд. мед. наук. СПб.; 2011. 24 c. [Musina E.V. Mechanisms of influence and efficacy of progesterone in fibrocystic breast disease in the reproductive age: Author. dis. ... Candidate. Med. Sciences. St. Petersburg.; 2011. 24 c.]
- Cordina-Duverger E., Truong T., Anger A., Sanchez M., Arveux P., Kerbrat P. et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One. 2013; 8(11): e78016. doi: 10.1371/journal.pone.0078016. eCollection 2013
- Casanova G., Spritzer P.M. Effects of micronized progesterone added to nonoral estradiol on lipids and cardiovascular risk factors in early postmenopause: a clinical trial. Lipids Health Dis. 2012;11: 133
- L’Hermite M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric. 2013; 16(Suppl. 1): 44-53
补充文件
